levofloxacin has been researched along with clinafloxacin in 25 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (clinafloxacin) | Trials (clinafloxacin) | Recent Studies (post-2010) (clinafloxacin) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 183 | 16 | 19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (32.00) | 18.2507 |
| 2000's | 13 (52.00) | 29.6817 |
| 2010's | 4 (16.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Asahina, Y; Fukuda, Y; Kimura, T; Takei, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Cormican, MG; Jones, RN; Marshall, SA | 1 |
| Hecht, DW; Wexler, HM | 1 |
| Goldstein, EJ | 1 |
| Arvieux, C; Avril, JL; Cartier, F; Jacquelinet, C; Michelet, C; Vu, N | 1 |
| Bauernfeind, A | 1 |
| Brookings, E; Gray, B; Nix, S; Robinson, A; Swiatlo, E; Waites, K | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Brisse, S; Fluit, AC; Köhrer, K; Martin, N; Milatovic, D; Scheuring, S; Schmitz, FJ; Verhoef, J | 1 |
| Hershberger, E; Rybak, MJ | 1 |
| Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H | 1 |
| Ferraro, MJ; Jorgensen, JH; Swenson, JM; Tenover, FC; Weigel, LM; Whitney, CG | 1 |
| Doern, GV; Ernst, EJ; Klepser, ME; Petzold, CR; Rhomberg, P | 1 |
| Appelbaum, PC; Davies, T; Edlund, C; El Amin, N; Oh, H | 1 |
| Rossi, C; Sternon, J | 1 |
| Furuhama, K; Itoh, S; Katoh, M | 1 |
| Piddock, L; Ricci, V | 1 |
| Cabeza, JG; Hernandez, J; Llagostera, M; Mensa, J; Montero, T; Ruiz Chaler, M; Sierra, JM; Vila, J | 1 |
3 review(s) available for levofloxacin and clinafloxacin
| Article | Year |
|---|---|
Quinolone antibiotics.
Topics: | 2019 |
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Safety; Syndrome | 1996 |
[Third and fourth generation fluoroquinolones].
Topics: Administration, Oral; Anti-Infective Agents; Aza Compounds; Belgium; Biological Availability; Drug Monitoring; Drug Resistance; Fluoroquinolones; Gemifloxacin; Humans; Intestinal Absorption; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Patient Selection; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors; Treatment Outcome | 2001 |
22 other study(ies) available for levofloxacin and clinafloxacin
| Article | Year |
|---|---|
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
Topics: Animals; Anti-Bacterial Agents; Benzoxazines; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Pyrrolidines; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
Topics: Anti-Infective Agents; Bacteria, Aerobic; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fleroxacin; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Spiro Compounds | 1995 |
In vitro susceptibility of anaerobes to quinolones in the United States.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Culture Media; Drug Resistance, Microbial; Evaluation Studies as Topic; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Quinolones; United States | 1996 |
Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sulfamethoxazole, or rifampin, against intracellular Listeria monocytogenes.
Topics: Amoxicillin; Anti-Infective Agents; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; HeLa Cells; Humans; Levofloxacin; Listeria monocytogenes; Ofloxacin; Quinolones; Rifampin; Sulfamethoxazole; Trimethoprim | 1997 |
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus | 1997 |
Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest.
Topics: Anti-Infective Agents; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Streptococcus pneumoniae | 1998 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterat
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Enterobacter cloacae; Fluoroquinolones; Gatifloxacin; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 1999 |
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Blood Coagulation; Ciprofloxacin; Fibrin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae | 2000 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2000 |
Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Streptococcus pneumoniae | 2000 |
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae; Time Factors | 2001 |
gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
Topics: Amino Acid Substitution; Anti-Infective Agents; Aza Compounds; Bacteroides fragilis; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines | 2001 |
In vivo photochemical micronucleus induction due to certain quinolone antimicrobial agents in the skin of hairless mice.
Topics: Animals; Anti-Infective Agents; Chromosome Aberrations; Dose-Response Relationship, Drug; Fluoroquinolones; Levofloxacin; Light; Male; Mice; Mice, Hairless; Micronuclei, Chromosome-Defective; Micronucleus Tests; Ofloxacin; Photosensitizing Agents; Quinolones; Skin; Time Factors | 2002 |
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Topics: Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Moxifloxacin; Mutagenicity Tests; Naphthyridines; Ofloxacin; Quinolines; Selection, Genetic; Staphylococcus aureus; Streptococcus pneumoniae | 2005 |